ArticleLeukemia2024
Prognostic impact of CEBPA mutational subgroups in adult AML.
Open access · hybridAbstract read
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
11.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 26 citations in OpenAlex.
- CCAAT/enhancer-binding protein alpha basic leucine zipper in-frame insertion/deletion (CEBPA bZIP-InDel-inf) defines a favourable-prognosis subgroup in CEBPA-mutated acute myeloid leukaemia.British journal of haematology · 2026Article
- FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.Research square · 2026Article
- FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.bioRxiv : the preprint server for biology · 2026Article
- Optimization of PCR amplification and sequencing of GC-rich protein-coding region of CEBPA (CCAAT/enhancer binding protein alpha) in acute myeloid leukemia patients using betaine.Molecular biology reports · 2026Article
- DNA Methylation Stochasticity Is Linked to Transcriptional Variability and Convergent Epigenetic Disruption across Genetic Subtypes of Acute Myeloid Leukemia.Cancer research · 2026Article
- Clinical and Prognostic Significance ofCancers · 2026Article
- The Mutational Landscape of Acute Myeloid Leukemia and Its Impact.International journal of molecular sciences · 2026Review
- Discovery of BEND4 as a novel single-gene prognostic marker and therapeutic target for adverse AML.NPJ precision oncology · 2026Article
- [Prognostic impact of WT1 mutations in patients with acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- [Prognostic significance of CEBPA gene mutations in acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- PSMG3 enhances the proliferation and metastasis of hepatocellular carcinoma via inhibiting HDAC6.Functional & integrative genomics · 2026Article
- A Review of CEBPA's Role in Hereditary Leukemia.EJHaem · 2026Review
- bZIP-Domain Variant Allele Frequency Helps to Refine Risk Stratification in CEBPA-Mutated AML.Biomedicines · 2026Article
- ELK1 promotes the progress of myeloid leukemia by hindering the differentiation of neutrophils.Experimental hematology & oncology · 2026Article
- Mutation Patterns Define Clinical Heterogeneity in Acute Myeloid Leukemia.Journal of Cancer · 2026Article
- More precise risk stratification for de novo acute myeloid leukemia with double-mutation CEBPA.Therapeutic advances in hematology · 2026Article
- A Mutational Landscape in Acute Myeloid Leukemia: Overview and Prognostic Impacts.Diagnostics (Basel, Switzerland) · 2025Review
- Rapid epigenomic classification of acute leukemia.Nature genetics · 2025Article
- Article
- A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 19 institutions in 4 countries.
Julia-Annabell GeorgiMedizinische Klinik und Poliklinik 1, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Sebastian StasikMedizinische Klinik und Poliklinik 1, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0003-0271-4894
Michael KramerAvenCell Europe GmbH, Dresden, Germany.
Manja MeggendorferMLL Münchner Leukämielabor GmbH, Munich, Germany.
Christoph RölligMedizinische Klinik und Poliklinik 1, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Torsten HaferlachMLL Münchner Leukämielabor GmbH, Munich, Germany.
Peter ValkErasmus University Medical Center, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0002-8857-9461
David LinchDepartment of Haematology, UCL Cancer Institute, London, UK.
Tobias HeroldLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-9615-9432
Nicolas DuployezInstitut de Recherche contre le Cancer de Lille, Centre Hospitalier Universitaire de Lille, Lille, France.ORCID http://orcid.org/0000-0002-3927-1022
Franziska TaubeMedizinische Klinik und Poliklinik 1, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Jan Moritz MiddekeMedizinische Klinik und Poliklinik 1, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Uwe PlatzbeckerKlinik und Poliklinik fur Hämatologie, Zelltherapie und Hämostaseologie, Universitätsklinikum Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0003-1863-3239
Hubert ServeMedizinische Klinik 2, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Claudia D BaldusKlinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0002-0748-834X
Carsten Muller-TidowKlinik für Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7166-5232
Claudia HaferlachMLL Münchner Leukämielabor GmbH, Munich, Germany.ORCID http://orcid.org/0000-0002-6333-5049
Sarah KochMLL Münchner Leukämielabor GmbH, Munich, Germany.
Wolfgang E BerdelDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Bernhard J WoermannGerman Society of Hematology and Oncology, Berlin, Germany.ORCID http://orcid.org/0000-0003-2273-5502
Utz KrugDepartment of Medicine 3, Klinikum Leverkusen, Leverkusen, Germany.
Jan BraessDepartment of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany.ORCID http://orcid.org/0000-0001-6528-2078
Wolfgang HiddemannDepartment of Medicine III, University Hospital LMU Munich, Munich, Germany.
Karsten SpiekermannDepartment of Medicine III, University Hospital LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-5139-4957
Emma L BoertjesErasmus University Medical Center, Rotterdam, Netherlands.
Robert K HillsNuffield Department of Population Health, Oxford University, Oxford, UK.
Alan BurnettDepartment of Haematology, Cardiff University, University Hospital of Wales, Cardiff, UK.
Gerhard EhningerAvenCell Europe GmbH, Dresden, Germany.
Klaus MetzelerKlinik und Poliklinik fur Hämatologie, Zelltherapie und Hämostaseologie, Universitätsklinikum Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0003-3920-7490
Maja Rothenberg-ThurleyDepartment of Medicine III, University Hospital LMU Munich, Munich, Germany.
Annika DufourDepartment of Medicine III, University Hospital LMU Munich, Munich, Germany.
Hervé DombretHôpital Saint-Louis (AP-HP), EA 3518, Université de Paris, Paris, France.
Cecile PautasService d'Hématologie et de thérapie cellulaire, Hôpital Henri Mondor, Créteil, France.
Claude PreudhommeInstitut de Recherche contre le Cancer de Lille, Centre Hospitalier Universitaire de Lille, Lille, France.
Laurene FenwarthInstitut de Recherche contre le Cancer de Lille, Centre Hospitalier Universitaire de Lille, Lille, France.ORCID http://orcid.org/0000-0003-2808-4843
Martin BornhäuserMedizinische Klinik und Poliklinik 1, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Rosemary GaleDepartment of Haematology, UCL Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0103-1787
Christian ThiedeMedizinische Klinik und Poliklinik 1, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. christian.thiede@uniklinikum-dresden.de.ORCID http://orcid.org/0000-0003-1241-2048
Klinik und Poliklinik für Psychotherapie und Psychosomatik · DELMU Klinikum · DEMunich Leukemia Laboratory (Germany) · DECentre Hospitalier Universitaire de Lille · FRCRUK Lung Cancer Centre of Excellence · GBErasmus MC · NLUniversity Hospital Leipzig · DECentre Hospitalier Universitaire Henri-Mondor · FRGerman Society of Surgery · DEGoethe University Frankfurt · DEHeidelberg University · DEKlinikum Leverkusen · DEKrankenhaus Barmherzige Brüder · DENational Center for Tumor Diseases · DEUniversité Paris Cité · FRUniversity Hospital Münster · DEUniversity Hospital of Wales · GBUniversity Hospital Schleswig-Holstein · DEUniversity of Oxford · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent refinements in the diagnostic and prognostic assessment of CEBPA mutations in AML, several questions remain open, i.e. implications of different types of basic region leucin zipper (bZIP) mutations, the role of co-mutations and the allelic state. Using pooled primary data analysis on 1010 CEBPA-mutant adult AML patients, a comparison was performed taking into account the type of mutation (bZIP: either typical in-frame insertion/deletion (InDel) mutations (bZIP
Indexed as
Leukemia, Myeloid, AcuteAdultCCAAT-Enhancer-Binding ProteinsFrameshift MutationHumansMutationPrognosisCCAAT-Enhancer-Binding ProteinsCEBPA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.